AmgenvsMonopar Therapeutics

AMGN and MNPR stock compared: price, dividend, valuation and results, from SEC filings.

AMGN

Amgen Inc.

$435.64

Value $235B

-0.72%
AMGN's page

MNPR

Monopar Therapeutics Inc.

$69.00

Value $591M

-1.84%
MNPR's page

Amgen (AMGN) has a market value of $235B and Monopar Therapeutics (MNPR) $591M. Over the last year, with dividends, AMGN moved +31.5% and MNPR -16.9%. Dividend yield: AMGN 2.31%, MNPR none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    AMGN$235B

    MNPR$591M

    AMGN is 398 times MNPR

  • Revenue, 12 months

    AMGN$38.9B

    MNPR$0

  • Net income, 12 months

    AMGN$9.4B

    MNPR-$21M

  • Operating margin

    AMGN32.4%

    MNPR–

  • ROIC

    AMGN16.2%

    MNPR-9.6%

    25.8 points apart

  • P/E

    AMGN25.0

    MNPR–

  • Dividend yield

    AMGN2.3%

    MNPR0.0%

    2.3 points apart

  • 5-year return

    AMGN+146.3%

    MNPR+193.0%

    46.7 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

AMGN+146.3%

MNPR+193.1%

020040020222023202420252026
Returns by period
PeriodAMGNWith dividendsMNPRWith dividends
1 year since November 19, 2025+31.5%Price +27.2%-16.9%Price -16.9%
3 years since November 20, 2023+79.2%+21.5% a yearPrice +64.2%+4,658.6%+262.4% a yearPrice +4,658.6%
5 years since November 19, 2021+146.3%+19.8% a yearPrice +111.4%+193.0%+24.0% a yearPrice +193.0%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

AMGNAmgenMNPRMonopar Therapeutics

Valuation

AMGNMNPR
Valuation
Price$435.64$69.00
Market value$235B$591M
Enterprise value (EV)$276B$486M
P/E25.0–
P/E, 5-year median23.0–
P/B16.44.7
EV/EBIT21.9–
Free cash flow yield4.1%–

Results and growth

AMGNMNPR
Results and growth
Revenue, 12 months$38.9B$0
Net income, 12 months$9.4B-$21M
Free cash flow, 12 months$9.6B-$16M
Earnings per share, 12 months$17.25-$2.44
Revenue growth, year on year10.0%–
Revenue growth a year, past+7.6%over 5 years–
EPS growth a year, past+2.9%over 5 years–

Margins and returns on capital

AMGNMNPR
Margins and returns on capital
Gross margin70.9%–
Operating margin32.4%–
Net margin24.1%–
ROIC16.2%-9.6%
ROE87.8%-15.3%

Balance sheet

AMGNMNPR
Balance sheet
Cash$13.2B$105M
Total debt$54.0B$357.3K
Net debt / EBITDA2.3–
Interest cover4.8×–

Dividends and buybacks

AMGNMNPR
Dividends and buybacks
Dividend yield2.3%–
Dividend per share, 12 months$10.08–
Dividend growth a year, past+8.1%over 5 years–
Buyback yield–5.9%
Shareholder yield2.3%5.9%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: AMGN or MNPR

Didn't find what you were looking for?

Ask us
Which is bigger, Amgen or Monopar Therapeutics?

By market value, Amgen ($235B) is about 397.5 times Monopar Therapeutics ($591M), at today's prices.

How did AMGN and MNPR stock do over the last 5 years?

Since November 19, 2021, AMGN's price moved +111.4% and MNPR's +193.0%. With dividends: AMGN +146.3% (+19.8% a year), MNPR +193.0% (+24.0% a year). Past returns do not predict future ones.

Which pays the higher dividend, AMGN or MNPR?

The dividend yield at today's price is 2.31% for Amgen and none for Monopar Therapeutics. Over the last twelve months they paid $10.08 and – per share.

Which is the better investment, Amgen or Monopar Therapeutics?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.